Lipids and statins: two targets and a three-month recheck

Clinical Rounds, the GPAtlas podcast. Cardiovascular. 19 minutes. Published 31 August 2026. Free to listen.

Clinical source: our own Ocean article "Lipid Modification - CVD Prevention", last reviewed 24 September 2025.

Transcript

Sarah: Hello, and welcome to GPAtlas Clinical Rounds. I'm Sarah, and this is the podcast where we take one thing you'll genuinely see this week and work out what to do with it.

Ben: And I'm Ben. Today, lipids. And the appointment that matters isn't the one where you start the statin.

Sarah: Mr Nowak is sixty-two, had a heart attack fourteen months ago, and he's on atorvastatin. He's here about his knee. And while I've got him open I look at his lipids, and there's a result from eleven months ago: non-HDL of three point one. Nobody did anything with it. It's not flagged, it's not abnormal-looking, it's just sitting there. And that is the commonest lipid failure in general practice, and it isn't a prescribing failure at all.

Ben: Three things. The two different targets, because primary and secondary prevention are graded completely differently. What to do when the target isn't met, which is escalate rather than accept. And the monitoring, including the two results that should never stop a statin and the one that must.

Sarah: So, two routes and two targets. Primary prevention: atorvastatin twenty milligrams daily, first-line. And the target is a percentage, not an absolute number. A greater than forty per cent reduction in non-HDL cholesterol at three months.

Ben: Secondary prevention is different in both respects. Atorvastatin eighty milligrams daily, whatever the baseline cholesterol, unless drug interactions, a high adverse-effect risk or patient preference indicate a lower dose. And the target is absolute: LDL at or below two point zero, or non-HDL at or below two point six.

Sarah: So Mr Nowak, secondary prevention, has a non-HDL of three point one against a target of two point six. He is not at target, and he's been not at target for eleven months, and nothing in the system said so, because three point one doesn't look abnormal on a screen. It only looks wrong if you know which of the two targets applies to him.

Ben: And the sentence our article uses is the one that should drive the whole review: if the target is not met, the answer is to optimise and escalate, not to accept the first response. Not to file it. Not to note partial improvement. Escalate.

Sarah: Forty per cent for primary. Two point six for secondary. Different questions.

Sarah: On timing, two practical things that make this easier than it used to be. You no longer need a fasting sample to start or monitor most patients. And the schedule is baseline, then recheck at three months after starting or changing the dose, with an annual non- fasting lipid measurement supporting ongoing secondary prevention review.

Ben: And one that matters in the days after an event: do not delay statin treatment after an acute coronary syndrome or for secondary prevention. You don't wait for a cholesterol result to start. The dose is eighty regardless of the number, so the number isn't gating anything.

Sarah: No fasting needed. And do not wait for a result to start.

Sarah: So he's not at target. What's the ladder? Our article's order is: check adherence, dose timing, diet and lifestyle, and up-titrate where tolerated. Then, if he's intolerant, switch to rosuvastatin or the more hydrophilic pravastatin. Then add ezetimibe ten milligrams daily if the target isn't met on the maximal tolerated statin, or use ezetimibe alone if statins are contraindicated or not tolerated.

Ben: And that's the end of the primary-care ladder. Bempedoic acid, bempedoic acid with ezetimibe, inclisiran, evolocumab and alirocumab all sit in our article under a heading that says specialist-only escalation. So they're the next step, but they're not your next step.

Sarah: Which is worth being clear about, because these drugs get a lot of coverage and patients ask for them by name. The honest answer is that they exist, they work, and the route to them is a referral rather than a prescription from me.

Ben: Adherence, up-titrate, ezetimibe. Then it is a referral.

Sarah: Monitoring, and this is where statins get stopped for the wrong reasons. Liver function: baseline, three months, twelve months, and then not again unless clinically indicated. And the rule that stops a lot of unnecessary stopping: do not exclude treatment for levels raised but below three times the upper limit of normal.

Ben: Creatine kinase is symptom-driven only. You check it if the patient has persistent generalised unexplained muscle symptoms before starting, or if they develop muscle symptoms on treatment. It is not measured routinely in asymptomatic patients, and a routine CK on a well patient generates a problem rather than solving one.

Sarah: And the two hard stop rules: stop the statin if the CK rises above five times the upper limit of normal, or if the ALT reaches and persists at three times the upper limit, and investigate other causes. Those are the numbers. Everything below them is a conversation, not a stop.

Ben: And for muscle symptoms with a CK below five times normal, our article describes a de- challenge and re-challenge approach: stop, let the symptoms settle, then restart at a lower dose or on a different statin. Which means statin intolerance is a conclusion you reach after a process, not a label you accept at the first complaint.

Sarah: Below three times normal is not a reason to stop.

Sarah: And the one that I think causes the most avoidable harm, because it feels so logical. New- onset diabetes. Statins cause a small increase in diabetes risk. And our article's instruction is unambiguous: monitor where appropriate, but never stop a statin on this basis alone, because the cardiovascular benefit outweighs it.

Ben: And you can see exactly how it happens. Someone's HbA1c creeps into the diabetic range, you're reviewing their medication looking for contributors, the statin is a known contributor, and stopping it feels like good medicine. And what you've actually done is take a post-infarct patient off the drug most likely to keep him alive, to modestly improve a number.

Sarah: Never stop a statin for new diabetes alone.

Sarah: Familial hypercholesterolaemia, which is the thing you're looking for in the background of every lipid result. Two referral numbers: refer for specialist assessment if the total cholesterol is above nine, or the non-HDL above seven point five. And case-find on clinically suspected FH, or a total cholesterol above seven point five with a family history of premature coronary heart disease.

Ben: And it runs on a different target from everything else we've said. FH sits outside NG238 and is managed under the separate NICE FH guideline, where the goal is a more than fifty per cent reduction in LDL from baseline. You offer a high-intensity statin, and you refer if a high-intensity statin plus ezetimibe doesn't achieve that.

Sarah: With one examination point that stops you being falsely reassured: absent tendon xanthomata do not exclude FH. So looking at somebody's Achilles tendons and finding nothing is not a rule-out, and the numbers are what refer, not the signs.

Ben: Nine, or seven point five non-HDL. And normal tendons prove nothing.

Sarah: Three quick ones that come up constantly. Simvastatin is metabolised by CYP3A4, so the dose has to be capped, for example twenty milligrams maximum with amlodipine, diltiazem or verapamil, and simvastatin eighty should be avoided altogether because of a recognised excess myopathy and rhabdomyolysis risk.

Ben: Triglycerides between ten and twenty: repeat with a fasting sample and review secondary causes, and seek specialist advice if persistently above ten. And aspirin: do not routinely offer it for primary prevention of cardiovascular disease. That one still turns up on repeat lists from a decade ago.

Sarah: And pregnancy: advise women planning pregnancy to stop the statin three months before conception, and not to restart until they've finished breastfeeding. Stop immediately if pregnancy is suspected. Which means a woman of childbearing age on a statin needs that conversation at the point of prescribing, not at the point of a positive test.

Ben: And our article gives a safety-netting line for the muscle question that I think is better than what most of us say: please tell us about any persistent muscle pain, we can pause the statin and check things rather than you simply stopping. That invites the phone call instead of the silent discontinuation, which is how most statins actually stop.

Sarah: Invite the phone call. Otherwise they just stop taking it.

Sarah: I want to go back to Mr Nowak, because the failure in his case is worth naming precisely. Nobody prescribed badly. He's on the correct drug at the correct dose for secondary prevention. Somebody did the right thing fourteen months ago. And then a result came back that was above his target and nothing happened, and that is a completely different kind of failure to a prescribing error.

Sarah: And it happens because three point one doesn't look wrong. It isn't flagged by the lab, because labs flag against population ranges, not against the target for this patient's risk category. So the number arrives looking normal, and the only thing that makes it abnormal is knowing he's secondary prevention and his target is two point six.

Ben: Which means this is a searchable problem rather than a remembering problem. Your post- infarct patients with a non-HDL above two point six are a list you can generate, and every one of them is someone on the right drug who is quietly not at target. That's a much higher-yield afternoon than most audit work.

Sarah: And the fix for most of them is not complicated. Check adherence first, because our article puts that at the top of the ladder for a reason, and a proportion of people at that stage are taking it intermittently or have stopped without telling anyone. Then up- titrate if there's room. Then ezetimibe ten milligrams. Most of that list resolves without anybody leaving primary care.

Ben: And the adherence conversation is worth having carefully rather than as an accusation, because the commonest reason a statin stops is muscle symptoms that were never reported. Which is exactly why our article's safety-netting wording matters: telling somebody in advance that you can pause it and check things, rather than them simply stopping, is what turns a silent discontinuation into a phone call.

Sarah: He is on the right drug and not at target. That is a search, not a memory.

Sarah: One more thing worth saying about the two targets, because it explains why this goes wrong so often. Primary prevention is graded on a percentage change, which needs a baseline. Secondary prevention is graded on an absolute number, which doesn't. So the same lipid result means different things depending on a fact that isn't in the result.

Ben: And if the baseline is missing, which it often is when someone transferred practices or started in hospital, the primary-prevention target becomes uncomputable. At which point people default to eyeballing the number, and eyeballing it is precisely what makes a three point one look acceptable.

Sarah: A percentage needs a baseline. An absolute number does not.

Sarah: And a last thought about why this particular failure is so common, which I think is worth naming because it isn't about lipids at all. Starting a drug is an event. It has a consultation attached, a decision, a conversation with the patient. Reviewing whether it worked is not an event. It's a number arriving in a queue.

Sarah: So all of the attention in the system, ours and the patient's, is at the start. And our article's whole emphasis is on the other end: the three-month recheck, the two targets, and the instruction to escalate rather than accept. That's where the benefit is, and it's the part with no appointment attached to it.

Ben: Which is why the practical recommendation from this one isn't a piece of knowledge, it's a search. Post-infarct patients with a non-HDL above two point six. Primary prevention patients with no three-month recheck at all. Both lists exist in every practice, and both are made of people who are already on the right drug.

Sarah: Starting is an event. Reviewing is a number in a queue.

Ben: And a short word on what not to over-monitor, because the other failure here is doing too much. Liver function is baseline, three months, twelve months, and then not again unless clinically indicated. Creatine kinase is symptom-driven and not measured routinely in asymptomatic patients. Fasting samples are no longer needed for most people.

Ben: So a well patient on a stable statin dose needs an annual non-fasting lipid for the secondary-prevention review and very little else. Adding routine liver function and CK to that is not caution, it generates borderline results that lead to statins being stopped for numbers that our own article says are not reasons to stop.

Sarah: Over-monitoring is how a good statin gets stopped.

Ben: Exam corner. A sixty-two year old man had a myocardial infarction fourteen months ago and takes atorvastatin eighty milligrams daily. His most recent non-HDL cholesterol, taken eleven months ago, is three point one millimoles per litre. He reports no side effects. What is the most appropriate action? A, no change, as he is on maximal statin therapy. B, check adherence and add ezetimibe ten milligrams daily. C, stop the statin and refer to lipid clinic. Or D, repeat the lipids in twelve months.

Ben: It's B. His secondary-prevention target is a non-HDL at or below two point six, and three point one is above it, so he is not at target. The article says the answer is to optimise and escalate, not accept the first response, and the primary-care escalation after a maximal tolerated statin is ezetimibe, having first checked adherence. A is the error the whole episode is about, treating maximal dose as job done. C throws away his most important drug. And D repeats the eleven months of nothing that already happened.

Sarah: So. Three things for Monday. One. Know which target you're looking at, because forty per cent and two point six are different questions and a result that looks fine may be neither. Two. Not at target means escalate, not accept, and in primary care that means adherence, up-titration, then ezetimibe. And three. Never stop a statin for new-onset diabetes, and don't stop it for liver enzymes below three times normal.

Sarah: One thing to reflect on, if you're logging this. Search your post-infarct patients for a non-HDL above two point six. How many have been sitting there, on the right drug, quietly not at target? The full transcript and the references are on the episode page. Ben and I are synthetic voices. The medicine isn't. See you next week.

More from Clinical Rounds

Every episode of Clinical Rounds, free to listen with a full transcript.